What are the common and serious side effects of albendazole?

Albendazole Side Effects

Albendazole's most serious side effects are bone marrow suppression (including potentially fatal granulocytopenia and pancytopenia), hepatotoxicity, and embryo-fetal toxicity, requiring mandatory monitoring of blood counts and liver enzymes every 2 weeks during treatment courses longer than 14 days. 1

Serious Adverse Effects Requiring Monitoring

Hematologic Toxicity

• Bone marrow suppression, aplastic anemia, and agranulocytosis can occur, with fatalities reported from granulocytopenia or pancytopenia. 1
• Leukopenia occurs in up to 10% of patients on chronic therapy. 2
• Monitor complete blood counts at the beginning of each 28-day treatment cycle and every 2 weeks during therapy. 1
• Discontinue albendazole immediately if clinically significant decreases in blood cell counts occur. 1
• Patients with pre-existing liver disease or hepatic echinococcosis require more frequent blood count monitoring due to increased risk. 1
• Recent pharmacovigilance data confirm significant disproportionality signals for bone marrow failure and hypoplastic anemia (adjusted ROR 9.44) and serious leukopenia (ROR 3.89) compared to other anthelmintics. 3

Hepatotoxicity

• Elevated liver enzymes occur in approximately 16% of patients, requiring drug discontinuation in 3.8% of cases. 2, 1
• Monitor liver transaminases before each treatment cycle and at least every 2 weeks during treatment. 1
• Consider discontinuing therapy if hepatic enzymes exceed twice the upper limit of normal. 1
• Transaminases typically normalize after prompt drug discontinuation. 2
• Cases of acute liver failure and hepatitis have been reported, though causality remains uncertain. 1, 4
• Pharmacovigilance analysis shows significant signals for serious hepatic disorders (adjusted ROR 3.10) and hepatitis (ROR 2.88). 3

Embryo-Fetal Toxicity

• Albendazole causes embryotoxicity and skeletal malformations in animal studies at doses 0.1 to 0.6 times the human dose. 1
• Obtain pregnancy testing in all females of reproductive potential before initiating therapy. 1
• Advise effective contraception during treatment and for 3 days after the final dose. 1

Treatment-Induced Inflammatory Side Effects (Neurocysticercosis)

Neurologic Symptoms

• The main side effects in neurocysticercosis patients are due to parasiticidal activity and treatment-induced inflammation, including headaches, seizures, and dizziness. 2
• A transient increase in seizure frequency occurs after therapy initiation. 2
• All neurocysticercosis patients must receive concomitant corticosteroids and anticonvulsant therapy to prevent cerebral hypertensive episodes, increased intracranial pressure, and focal neurologic signs. 1
• Recent pharmacovigilance data identified a new signal for seizures with benzimidazole derivatives not previously mentioned in product labeling. 3

Retinal Damage Risk

• Perform fundoscopic examination before initiating anthelmintic therapy in all neurocysticercosis patients. 2
• If retinal lesions are visualized, weigh the need for therapy against the risk of retinal damage from albendazole-induced parasite death. 1

Common Adverse Effects (Generally Mild)

Gastrointestinal Effects

• Abdominal pain occurs in 6% of hydatid disease patients and 0% of neurocysticercosis patients. 1
• Nausea and vomiting each occur in 4% of hydatid disease patients and 6% of neurocysticercosis patients. 1
• In mass drug administration programs, vomiting was the most common adverse effect, with an overall incidence of only 1.37 per 1000 recipients. 5

Other Common Effects

• Headache occurs in 11% of neurocysticercosis patients and 1% of hydatid disease patients. 1
• Reversible alopecia occurs in 2% of hydatid disease patients. 1
• Dizziness and vertigo each occur in 1% of patients. 1
• Fever occurs in 1% of hydatid disease patients. 1

Hypersensitivity Reactions

• Rash and urticaria have been reported at less than 1% incidence. 1
• Pharmacovigilance data show a signal for serious urticaria (ROR 2.02). 3

Critical Monitoring Requirements

For treatment courses >14 days:

• Monitor hepatotoxicity and leukopenia (strong recommendation, moderate quality evidence). 2
• No additional monitoring is needed when combining albendazole with praziquantel beyond standard albendazole monitoring. 2

For single-dose or short-course therapy (<14 days):

• Routine laboratory monitoring is not required. 6
• All reported adverse effects in mass administration programs were mild in nature. 5

Overdose Manifestations

• A case of severe overdose (113.6 g over 3 weeks) resulted in pancytopenia (WBC 0.4 × 10³/mm³, ANC 0), transaminase elevation (AST 268 IU/L), and complete alopecia. 7
• Recovery occurred with supportive care including antibiotics and colony-stimulating factors. 7

Important Clinical Pitfalls

• Patients with elevated baseline liver enzymes are at increased risk for both hepatotoxicity and bone marrow suppression. 1
• Undiagnosed neurocysticercosis may be unmasked in patients treated for other conditions; evaluate at-risk patients before initiating therapy. 1
• Albendazole absorption improves up to five-fold when taken with food, especially fatty meals; always administer with food. 2, 6, 1
• Underreporting of adverse effects is common, as anthelmintics are often considered low-risk medications. 8